Login to Your Account

Neuromed Licenses Late-Stage Pain Drug From ALZA For $30M

By Trista Morrison

Wednesday, April 25, 2007
Neuromed Pharmaceuticals' rationale for paying $30 million up front plus milestones and royalties to Johnson & Johnson subsidiary ALZA Corp. in exchange for U.S. rights to OROS Hydromorphone might not be intuitively obvious. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription